Ke Su

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Affiliated Hospital of Southwest Medical University, Inner Mongolia Electric Power (China), National Cancer Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, First Affiliated Hospital of Zhengzhou University, Shandong First Medical University · ORCID：0000-0002-7948-6335

发表论文 80 篇 · 总被引 1063 次 · h-index 20

代表论文

• Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period (2023 · Frontiers in Immunology · 被引 42)
• Construction and Validation of TACE Therapeutic Efficacy by ALR Score and Nomogram: A Large, Multicenter Study (2023 · Journal of Hepatocellular Carcinoma · 被引 42)
• Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma (2024 · Clinical & Translational Oncology · 被引 21)
• PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis (2023 · Journal of Hepatocellular Carcinoma · 被引 21)
• Machine Learning Radiomics for Predicting Response to MR-Guided Radiotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study (2025 · Journal of Hepatocellular Carcinoma · 被引 19)
• Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study (2024 · Annals of Hepatology · 被引 12)